Suppression of Retinal Neovascularization by Erythropoietin siRNA in a Mouse Model of Proliferative Retinopathy
Open Access
- 1 March 2009
- journal article
- retina
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 50 (3), 1329-1335
- https://doi.org/10.1167/iovs.08-2521
Abstract
Purpose. Erythropoietin (EPO), an oxygen-regulated hormone stimulating erythrocyte production, was recently found to be critical for retinal angiogenesis. EPO mRNA expression levels in retina are highly elevated during the hypoxia-induced proliferation phase of retinopathy. The authors investigated the inhibition of retinal EPO mRNA expression with RNA interference as a potential strategy to suppress retinal neovascularization and to prevent proliferative retinopathy. methods. The authors used a mouse model of oxygen-induced retinopathy. Retinal EPO and Epo receptor (EpoR) expression during retinopathy development were quantified with real-time RT-PCR in whole retina and on laser-captured retinal vessels and neuronal layers. Retinal hypoxia was assessed with an oxygen-sensitive hypoxyprobe. A small interference RNA (siRNA) targeting EPO or control negative siRNA was injected intravitreally at postnatal (P) day 12, P14, and P15 during the hypoxic phase, and the effect on neovascularization was evaluated in retinal flatmounts at P17. results. Retinal EPO mRNA expression in total retina was suppressed during the initial phase of vessel loss in retinopathy and was significantly elevated during the hypoxia-induced proliferative phase in all three neuronal layers in the retina, corresponding to an increased level of retinal hypoxia. EpoR mRNA expression levels also increased during the second neovascular phase, specifically in hypoxia-induced neovascular vessels. Intravitreous injection of EPO siRNA effectively inhibited approximately 60% of retinal EPO mRNA expression and significantly suppressed retinal neovascularization by approximately 40%. conclusions. Inhibiting EPO mRNA expression with siRNA is effective in suppressing retinal neovascularization, suggesting EPO siRNA is a potentially useful pharmaceutical intervention for treating proliferative retinopathy.This publication has 28 references indexed in Scilit:
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3Nature, 2008
- Erythropoietin deficiency decreases vascular stability in miceJCI Insight, 2008
- On future’s doorstep: RNA interference and the pharmacopeia of tomorrowJCI Insight, 2007
- Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathyBritish Journal of Ophthalmology, 2007
- Strategies for silencing human disease using RNA interferenceNature Reviews Genetics, 2007
- T2-TrpRS Inhibits Preretinal Neovascularization and Enhances Physiological Vascular Regrowth in OIR as Assessed by a New Method of QuantificationInvestigative Ophthalmology & Visual Science, 2006
- Anti-Epo receptor antibodies do not predict Epo receptor expressionBlood, 2006
- Retinal angiogenesis in development and diseaseNature, 2005
- Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic RetinopathyThe New England Journal of Medicine, 2005
- Inhibition of Ocular Angiogenesis by siRNA Targeting Vascular Endothelial Growth Factor Pathway Genes: Therapeutic Strategy for Herpetic Stromal KeratitisThe American Journal of Pathology, 2004